menu
    • menu
    [{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Neurology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"BTG Specialty Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Ohara Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Glucarpidase

    Menu

    Glucarpidase

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : SERB Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            M8 Pharmaceuticals Signs Exclusive Agreement with SERB to Bring Voraxaze® to Latin America

                            Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : SERB Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Serb

                            Belgium arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Serb

                            Belgium arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SERB Receives Positive CHMP Opinion for Voraxaze® (Glucarpidase) as Rescue Therapy for High Dose Methotrexate...

                            Details : Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further system...

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            November 25, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ohara Pharmaceutical

                            Japan arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ohara Pharmaceutical

                            Japan arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze® in The U...

                            Details : Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.

                            Product Name : Megludase

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 28, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BTG Specialty Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            BTG Specialty Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Serb

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicin...

                            Details : BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            February 03, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Serb

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BTG Specialty Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            BTG Specialty Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase,Methotrexate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BTG Specialty Pharmaceuticals Reports Initial Study Results Show Feasibility of Outpatient Methotrexate Admini...

                            Details : An ongoing arm of the study triggered by the difficult circumstances created by the COVID-19 pandemic is exploring the planned use of Voraxaze® (glucarpidase) to enable high dose MTX treatment of CNSL on an outpatient basis.

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Glucarpidase,Methotrexate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BTG Specialty Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            BTG Specialty Pharmaceuticals

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase,Methotrexate,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Underway to Examine the Planned Use of BTG Pharmaceutical's Voraxaze® with Methotrexate in CNS Lymphoma

                            Details : In this study, adult patients with isolated CNSL are treated with rituximab and methotrexate administered for eight cycles. Voraxaze® is given 24 hours following start of each methotrexate infusion.

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 23, 2020

                            Lead Product(s) : Glucarpidase,Methotrexate,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth